Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Crohns Disease Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

100 recruiting trials for Crohns Disease. Eligibility criteria explained in plain English.

TrialFinderData lists 100 Crohns Disease clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 3 is the largest group at 26% (8 studies); the largest phase groups are Phase 3: 8, Phase 4: 8, Phase 2: 7, Phase 1 / Phase 2: 5.

Research is led by AbbVie (4), Massachusetts General Hospital (4), Xiang Gao (3), among the most active sponsors registered for these trials.

The most frequently studied intervention is Placebo (drug, 7 trials), followed by Risankizumab, Upadacitinib.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
100
Total Trials
100
Recruiting Now
8
Phase 3 Trials
10
Sponsors

Track Crohns Disease trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT06512597

Behavioral Therapy for Crohn's Disease

People living with Crohn's disease (CD) experience psychological and emotional symptoms, in addition to known chronic and disabling physical symptoms, which prevent them from...

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 1702 locations
RECRUITINGNCT07364734

Epidemiological Characteristics and Efficacy Evaluation of Difficult-To-Treat Crohn's Disease

Difficult to treat Crohn's disease (DTT-CD) was defined by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) in 2023, which refers to CD patients...

Sponsor: Xiang GaoEnrolling: 14001 location
RECRUITINGNCT04760964

Mitochondrial DAMPs as Mechanistic Biomarkers of Mucosal Inflammation in Crohn's Disease and Ulcerative Colitis

The MUSIC study is a multi-centre, longitudinal study set in the real world IBD clinical setting to investigate and develop a new biomarker approach that aims to inform both...

Sponsor: University of EdinburghEnrolling: 2503 locations
RECRUITINGPhase 2NCT06309472

Trial of Mirtazapine for Depression in IBD

This study will test whether it is feasible to conduct a clinical trial of mirtazapine (an antidepressant tablet) in patients who have both depression and inflammatory bowel...

Sponsor: King's College LondonEnrolling: 764 locations
RECRUITINGNCT04859088

Biologics and Partial Enteral Nutrition Study

Crohn's disease (CD) is a chronic, incurable condition associated with inflammation in the gut lining. It causes diarrhoea, severe abdominal pain, poor nutrition and adversely...

Sponsor: NHS Greater Glasgow and ClydeEnrolling: 804 locations
RECRUITINGPhase 3NCT05995353

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves...

Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess...

Sponsor: AbbVieEnrolling: 11020 locations
RECRUITINGNCT05332639

Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility

The aim of this study is to develop and assess the feasibility and effect of a web-based, personalized risk-estimation for Crohn's disease (PRE-Crohn's) tool on behaviors and...

Sponsor: Massachusetts General HospitalEnrolling: 801 location
RECRUITINGNCT07385807

Exploring Fecal Calprotectin Levels, Maternal and Infant Microbiota, Infant Health, Nutrition, and Adverse Pregnancy...

The goal of this prospective longitudinal cohort study is to examine how the human microbiome of pregnant women-including bacteria and fungi in the gastrointestinal tract, vaginal...

Sponsor: University of British ColumbiaEnrolling: 802 locations
RECRUITINGNCT06956703

NAZA - Nottingham/Astra ZenecA Prospective IBD Cohort Study

The goal of this observational study is to learn about the comparisons of inflammatory markers between IBD and non-IBD (control) participants. The main question it aims to answer...

Sponsor: University of NottinghamEnrolling: 2401 location
RECRUITINGNCT06710067

Urine Metabolites in the Diagnosis of Disease

The goal of this observational study is to validate a non-invasive, urine-based diagnostic technology for the detection and differentiation of various gastrointestinal (GI)...

Sponsor: Luventix, Inc.Enrolling: 12504 locations
RECRUITINGPhase 4NCT05552287

Pharmacokinetic Infliximab Data in Pediatric Crohn's Disease

Rationale: Crohn's disease (CD) is a chronic, debilitating inflammatory bowel disease (IBD) which is diagnosed during childhood in up to one in ten patients. The use of anti-tumor...

Sponsor: Erasmus Medical CenterEnrolling: 501 location
RECRUITINGNCT06995170

Investigation of the Correlation Between Polyamine Levels and Their Key Enzymatic Activities in Association With...

Inflammatory Bowel Disease (IBD), encompassing Ulcerative Colitis (UC) and Crohn's Disease (CD), significantly impairs patients' quality of life. Current monitoring of disease...

Sponsor: Xijing HospitalEnrolling: 1461 location
RECRUITINGNCT06780683

Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease

Inflammatory Bowel Disease (IBD), which encompasses ulcerative Colitis (UC) and Crohn's Disease (CD), has seen significant improvements in patient outcomes with biologic...

Sponsor: Xiang GaoEnrolling: 1746 locations
RECRUITINGEarly Phase 1NCT06562361

A Microdose Trial Investigating Binding of [68Ga]Ga-DOTA-CYS-ATH001 in Healthy Subjects and Different Patient Groups.

The goal of this clinical trial is to use positron emission tomography (PET) to evaluate and compare the binding of the novel tracer \[68Ga\]Ga-DOTA-Cys-ATH001 in the liver and/or...

Sponsor: Antaros MedicalEnrolling: 303 locations
RECRUITINGNCT07245394

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

The SHIFT-IBD Study is being conducted at multiple medical centers across Canada to evaluate how well guselkumab (Tremfya) works for people with inflammatory bowel disease (IBD)...

Sponsor: TIDHI Innovation Inc.Enrolling: 2009 locations
RECRUITINGPhase 4NCT07303686

De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis

The goal of this clinical trial is to evaluate whether disease remission can be maintained when biologic therapy is reduced in patients with Crohn"s disease (CD) and ulcerative...

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health CentreEnrolling: 1151 location
RECRUITINGNCT03983473

Identification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease.

The MICROSPA project aims to compare gut microbiota, serum cytokines, and PBMC of patients suffering from Crohn's disease (CD) associated or not to spondylarthritis (SpA). 3...

Sponsor: Central Hospital, Nancy, FranceEnrolling: 2402 locations
RECRUITINGNCT07529236

Digestive Evolution of Children With Crohn's Disease or Ulcerative Colitis Whose Anti-TNFα Treatment Was Switched to...

Inflammatory bowel diseases (IBD) include Crohn's disease (CD) and ulcerative colitis (UC). They cause abdominal pain and chronic diarrhea and/or rectal bleeding, which can lead...

Sponsor: Centre Hospitalier Universitaire de NiceEnrolling: 401 location
RECRUITINGNCT06505304

AI-enabled Endoscopic Prediction of Post-operative Recurrence in Crohn's Disease

This is a multicentre prospective international observational study. This study aims to introduce a novel multidimensional approach to precision imaging, enabling the...

Sponsor: University College CorkEnrolling: 22515 locations
RECRUITINGNCT06800326

Diagnostic Concordance of MR Enterography and Ultrasound for Treatment Response Assessment in Crohn's Disease (MANTRA)

Crohn's disease is a lifelong condition resulting in inflammation of the bowel. Treatment with powerful drugs aim to reduce inflammation by suppressing the immune system. It is...

Sponsor: University College, LondonEnrolling: 1551 location
RECRUITINGNCT06896305

Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective,...

This clinical study protocol aims to prospectively compare the efficacy of standard therapy with anti-TNF agents combined with the Crohn's Disease Exclusion Diet (CDED) versus...

Sponsor: IRCCS Ospedale San RaffaeleEnrolling: 801 location
RECRUITINGPhase 1 / Phase 2NCT07629245

Tolerance of Local Administration of Cryopreserved Autologous Stromal Vascular Fraction Combined With Micrograft for...

The ADICROHN-3 study is a prospective, multicenter, open-label cohort study. Its design is supported by the following elements: * The results of the ADICROHN pilot study...

Sponsor: Assistance Publique Hopitaux De MarseilleEnrolling: 251 location
RECRUITINGNCT05645055

Biologics for Stricturing Crohn's Diseases

Recent researches have reported that biologics might be also effective for stricturing CD. However, the data were largely retrospective. Prospective studied are needed for...

Sponsor: Jinling Hospital, ChinaEnrolling: 2001 location
RECRUITINGNCT07532213

A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab

The purpose of this study is to evaluate how long guselkumab remains in participants with moderate to severe crohn's disease (CD) or ulcerative colitis (UC) in real-world setting....

Sponsor: Janssen-Cilag A.G., SwitzerlandEnrolling: 501 location
RECRUITINGPhase 4NCT07510191

TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response

This multicenter, randomized, controlled trial aims to evaluate the efficacy and safety of standard-dose tumor necrosis factor inhibitor (TNFi) plus low-dose upadacitinib compared...

Sponsor: Sixth Affiliated Hospital, Sun Yat-sen UniversityEnrolling: 3121 location
RECRUITINGNCT05321758

Fecal Microbiota Transplantation as the First-line Treatment in Active Pediatric Crohn's Disease

To explore the safety and effectiveness of repeated and multiple fecal microbiota transplantations (FMTs) plus partial enteral nutrition (PEN) as a first-line treatment for active...

Sponsor: Tongji HospitalEnrolling: 501 location
RECRUITINGPhase 3NCT06430801

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's...

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary...

Sponsor: Merck Sharp & Dohme LLCEnrolling: 120020 locations
RECRUITINGNCT06810518

ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool

The ALPCO Calprotectin CLIA is an in vitro diagnostic test intended to quantitatively measure concentrations of fecal calprotectin in human stool samples. Calprotectin is a...

Sponsor: American Laboratory Products CompanyEnrolling: 2203 locations
RECRUITINGNCT04846959

Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed...

The objective of this registry is to compare outcomes of risankizumab-exposed pregnancies with those of pregnancies that were not exposed to risankizumab among women with plaque...

Sponsor: AbbVieEnrolling: 8182 locations
RECRUITINGNCT05683730

Intermittent Caloric Restriction in Patients With Mild to Moderate Crohn's Disease

Crohn's disease (CD) is a chronic inflammatory disease of the gastrointestinal (GI) tract. CD is a common inflammatory bowel disease (IBD), frequent (150,000 patients in France...

Sponsor: Central Hospital, Nancy, FranceEnrolling: 1741 location
RECRUITINGNCT04973423

STUDY OF THE ADDED VALUE OF A TRANSMURAL EVALUATION IN PATIENTS WITH CROHN'S DISEASE UNDER BIOTHERAPY WITH CLOSE FECAL...

Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) that can dramatically affect the quality of life of patients. Due to its transmural nature (involvement of the...

Sponsor: University Hospital, Clermont-FerrandEnrolling: 18017 locations
RECRUITINGPhase 1 / Phase 2NCT03847467

Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF...

Randomized, placebo-controlled dose-ranging study of 2'-FL in IBD, Crohn's Disease (CD) and ulcerative colitis (UC). The overarching hypothesis is that 2'-FL supplementation in...

Sponsor: Children's Hospital Medical Center, CincinnatiEnrolling: 1163 locations
RECRUITINGPhase 2NCT07300553

Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease

Inflammatory Bowel Disease (IBD) often leads to poor disease control and reduced quality of life. Changes in the gut microbiota may disrupt the energy metabolism of immune cells,...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 451 location
RECRUITINGNCT05420233

The CROCO Study: CROhn's Disease COhort Study

The investigators propose to create a prospective Crohn Disease cohort, where patients receiving the most up-to-date therapies with a treat-to-target strategy, will be closely...

Sponsor: GLSMED Learning Health S.A.Enrolling: 60020 locations
RECRUITINGNCT07441447

Evaluation of Muscle Strength and Muscle Mass in Patients With Inflammatory Bowel Disease

This prospective observational study aims to evaluate the validity of ultrasonographic muscle measurements in patients with inflammatory bowel disease (IBD). Sarcopenia is...

Sponsor: Sakarya UniversityEnrolling: 1001 location
RECRUITINGNCT05113095

A Survey of Darvadstrocel in People With Crohn's Disease

This study is a survey in Japan of Darvadstrocel injection used to treat Crohn's disease people with complicated anal fistula. The study sponsor will not be involved in how the...

Sponsor: TakedaEnrolling: 2751 location
RECRUITINGPhase 4NCT06045754

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab...

Sponsor: TakedaEnrolling: 10020 locations
RECRUITINGNCT05698745

Immunological Characteristics of Preclinical IBD

The purpose of this study is to evaluate disease progression, in terms of development of symptomatic disease and complications associated with IBD (e.g. fistula, abscess,...

Sponsor: Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis UlcerosaEnrolling: 45020 locations
RECRUITINGNCT06104631

A Prospective Trial in Patients With Crohn's Disease in Remission and Having Irritable Bowel Syndrome-like Symptoms

Crohn's disease is a chronic and complex inflammatory bowel disease affecting the gastrointestinal tract, causing symptoms like abdominal pain, diarrhea, and fatigue. While its...

Sponsor: Biokuris s.a.Enrolling: 502 locations
RECRUITINGPhase 4NCT06997965

Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD

This is an open-label, single-arm, phase 4 study to assess the safety and efficacy of mirikizumab in approximately 60 participants with stricturing CD.

Sponsor: Alimentiv Inc.Enrolling: 602 locations
RECRUITINGPhase 2NCT07113522

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study...

Sponsor: Mirador Therapeutics, Inc.Enrolling: 14020 locations
RECRUITINGNCT06298188

Risankizumab in Children With Crohn's Disease (RisaKids)

The goal of this observational study is to to prospectively explore the real life short (12 weeks) and longer term (54 weeks) clinical, biochemical and endoscopic outcomes of...

Sponsor: Shaare Zedek Medical CenterEnrolling: 901 location
RECRUITINGNCT06858553

AI-Assisted MRE for Intestinal Fibrosis in Crohn's Disease

Intestinal fibrotic strictures represent a severe complication of Crohn's disease (CD), affecting over half of the patients. Despite the continuous emergence of novel medications,...

Sponsor: Minhu ChenEnrolling: 2345 locations
RECRUITINGNCT06629194

Validation of Scoring Systems for Differentiating Intestinal Tuberculosis from Crohn's Disease

Differentiating CD from intestinal tuberculosis (ITB) is difficult due to the low sensitivities of currently available diagnostic tests. The Asia-Pacific guideline recommends...

Sponsor: Mahidol UniversityEnrolling: 842 locations
RECRUITINGNCT07377188

Pregnancy and Inflammatory Bowel Disease

Inflammatory Bowel disease, including Crohn's disease and Ulcerative Colitis, are chronic diseases. Diagnosis is most often done in women of childbearing age. IBD can have and...

Sponsor: Centre Hospitalier Universitaire, AmiensEnrolling: 9451 location
RECRUITINGPhase 1 / Phase 2NCT06721962

Treatment of Moderate to Severe Refractory Crohn's Disease

This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn's Disease (CD). The primary purpose...

Sponsor: Tr1X, Inc.Enrolling: 3913 locations
RECRUITINGNCT07539727

Clinical Value of Intestinal Ultrasound in Predicting Clinical Relapse in Crohn's Disease Patients in Deep Remission: a...

Crohn's disease (CD) is a nonspecific chronic inflammatory condition characterized by a protracted course with alternating periods of relapse and remission. Even patients who...

Sponsor: Nanfang Hospital, Southern Medical UniversityEnrolling: 4201 location
RECRUITINGPhase 3NCT06332534

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to...

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many...

Sponsor: AbbVieEnrolling: 11020 locations
RECRUITINGNCT06146816

The Assessment of Infrared Treatment for Crohn's Disease

The goal of this clinical trial is to test the safety and efficacy of far Infra-red (fIR) therapy in Crohn's disease patients. The main questions it aims to answer are: 1. Is...

Sponsor: Shmuel Kivity, MDEnrolling: 401 location
RECRUITINGNCT06252493

Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.

In this study twenty-five (25) subjects with Crohn's disease scheduled for possible surgical intervention will be recruited for this study and a PET/MR scan using the...

Sponsor: Massachusetts General HospitalEnrolling: 251 location

Showing 50 of 100 trials.Search all Crohns Disease trials

Frequently Asked Questions

There are currently 100 clinical trials for Crohns Disease, with 100 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Crohns Disease, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 8 Phase 3 trials for Crohns Disease, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.